MedTrace Logo

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

NCT00199862 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-07-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether our drug, 124I-huA33, can safely detect colorectal cancer.

Conditions

Interventions

DRUG

Iodine-124 labeled humanized A33 (antibody)

Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.

Sponsors & Collaborators

Principal Investigators

  • Neeta Pandit-Taskar, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2025-07-02
Completion
2025-07-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199862 on ClinicalTrials.gov